Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
103 hedge funds and large institutions have $626M invested in Akero Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 35 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
6% more funds holding
Funds holding: 97 → 103 (+6)
0.64% more ownership
Funds ownership: 79.66% → 80.3% (+0.64%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less capital invested
Capital invested by funds: $700M → $626M (-$74.2M)
20% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 35
98% less call options, than puts
Call options by funds: $51K | Put options by funds: $2.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPW
Kore Private Wealth
New York
|
+$6.91M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.83M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.68M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.03M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$908K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$5.72M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$2.66M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$2.63M |
| 4 |
Two Sigma Investments
New York
|
-$1.84M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.7M |
AKRO Hedge Fund Activity: Q3 2021 in Review
103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2021, worth a combined $626M — down 11% from $700M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AKRO positions and 3 closed out — a net gain of 6 holders — while 28 added to existing stakes and 35 trimmed.
The largest buyer was Kore Private Wealth, opening a new position worth an estimated $6.91M. The largest seller was Janus Henderson Group, cutting an estimated $5.72M.
- 103 institutional investors held Akero Therapeutics (AKRO) as of Q3 2021, up from 97 in Q2 2021.
- Funds reported $626M of Akero Therapeutics stock for Q3 2021, down 11% quarter-over-quarter.
- 9 funds opened new Akero Therapeutics positions in Q3 2021 and 3 closed out, a net change of +6 holders.
- The largest Akero Therapeutics buyer in Q3 2021 was Kore Private Wealth, an estimated $6.91M added.
- The largest Akero Therapeutics seller in Q3 2021 was Janus Henderson Group, an estimated $5.72M sold.
Based on aggregated 13F filings for Q3 2021.